跳转至内容
Merck

B2134

Sigma-Aldrich

2-Bromo-α-ergocryptine methanesulfonate salt

solid

别名:

(+)-2-Bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)ergotaman-3′,6′-18-trione methanesulfonate salt, (+)-Bromocriptine methanesulfonate salt, Bromocriptine mesylate salt

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C32H40BrN5O5 · CH4SO3
CAS号:
分子量:
750.70
Beilstein:
4115238
EC號碼:
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

形狀

solid

光學活性

[α]20/D +95°, c = 1 in methanol: methylene chloride (1:1)(lit.)

顏色

white

溶解度

H2O: 0.8 mg/mL
ethanol: 23 mg/mL

儲存溫度

2-8°C

SMILES 字串

CS(O)(=O)=O.[H][C@@]12Cc3c(Br)[nH]c4cccc(C1=CC(CN2C)C(=O)N[C@@]5(O[C@]6(O)N([C@@H](CC(C)C)C(=O)N7CCC[C@@]67[H])C5=O)C(C)C)c34

InChI

1S/C32H40BrN5O5.CH4O3S/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18;1-5(2,3)4/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39);1H3,(H,2,3,4)/t18?,23-,24+,25+,31-,32+;/m1./s1

InChI 密鑰

NOJMTMIRQRDZMT-NEKRQHSLSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

應用

2-Bromo-α-ergocryptine methanesulfonate salt has been used:
  • as D2 agonist in bird zebra finches
  • for Prl secretion inhibitor in mice
  • for the inhibition of motility in planaria worm

生化/生理作用

Bromocriptine is an ergot alkaloid and a dopamine D2 receptor agonist. It is prescribed for Parkinson′s disorder, hyperprolactinemia and galactorrhoea. It modulates β cells of the pancreas from insulin hypersecretion and improves the metabolic profile in type 2 diabetes patients with obesity. It also modulates glutamate release by glutamate transporter,GLT-1.

象形圖

Exclamation markEnvironment

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 1

1 of 1

Y Zhang et al.
Metabolism: clinical and experimental, 48(8), 1033-1040 (1999-08-25)
Our previous studies have shown that the dopaminergic D1 receptor agonist SKF38393 (SKF) plus the D2 receptor agonist bromocriptine (BC) act synergistically to reduce obesity in obese C57BL/6J (ob/ob) mice. The present study investigated the effects of this combination on
M Geurts et al.
Brain research, 841(1-2), 135-142 (1999-11-05)
The role of dopamine receptor-G protein coupling in the development of striatal dopamine receptor supersensitivity was studied in rats with a 6-hydroxydopamine (6-OHDA)-induced unilateral lesion of the nigrostriatal pathway. This coupling was assessed by the measurement of dopamine agonist-induced guanosine
M Velasco et al.
American journal of therapeutics, 5(1), 37-43 (1999-03-31)
Dopamine is a biogenic amine synthesized in the hypothalamus, in the arcuate nucleus, the caudad, and various areas of the central and peripheral nervous system. It has been widely established that dopamine and its agonists play an important role in
The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells.
Van W, et al.
Biochemical Pharmacology, 79(12), 1827-1836 (2010)
S Perachon et al.
European journal of pharmacology, 366(2-3), 293-300 (1999-03-19)
We measured the affinities of bromocriptine, pramipexole, pergolide and ropinirole at human recombinant dopamine D1, D2 and D3 receptors in binding and functional tests. All four compounds bound with high affinity at the dopamine D3 receptor; bromocriptine and pergolide also

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门